Deutsche Bank Chooses CL

6th November 2017


We are thrilled to announce that Deutsche Bank's UK staff have chosen Cure Leukaemia as one of their official charity partners for 2018 & 2019. This transformational partnership, worth at least £2m over two years, will have a direct impact on Cure Leukaemia's work giving thousands more blood cancer patients across the UK access to pioneering treatments for the disease. This partnership will not only help save thousands of lives it will also hasten global progress towards the eradication of all forms of blood cancer within 25 years.

We will be communicating much more information regarding the partnership in the coming weeks and months as we look forward to a truly transformational next chapter for this great charity.

Our £1m Appeal to expand the Centre for Clinical Haematology at the Queen Elizabeth Hospital continues and we will be focussing on ensuring this equally transformational project is fully funded by December 31st 2017 before the Deutsche Bank partnership begins officially on January 2nd.

We simply could not have achieved this without the phenomenal support of the entire #CLFamily. Everyone played their part in spreading the word throughout the voting process and it typified how special our supporters are. To everyone who helped, thank you so, so much.

In case you missed any of our amazing video messages of support you can still watch these HERE.

Two patients who were instrumental in the cavassing campaign had these messages for the staff who voted for the charity:

 

   

< Back to List

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell